Key result
Trial evaluates asundexian versus placebo across Framingham risk categories after non-cardioembolic stroke or TIA.
Expert reaction
AHA Scientific Sessions 2026
0 experts have reacted so far. We show the split once 3 have.
Expert labels are toward OCEANIC-STROKE's result, from named public quotes (n=0). As of Oct 22, 2026.
FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial
FXIa inhibition by asundexian in participants with non-cardioembolic stroke or transient ischemic attack by non-laboratory Framingham risk score category: outcomes in the OCEANIC-STROKE randomized, placebo-controlled trial. Session: LBS.02. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
A 2026 study studied this question. Asundexian for FXIa inhibition is being evaluated against placebo across Framingham risk score categories in patients with non-cardioembolic stroke or TIA, with trial results currently pending.